Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly

Biomaterials

Volumn 33, Issue 27, 2012, Pages 6580-6591

  Hu, Qinglian ^a   Li, Wen ^a   Hu, Xiurong ^a   Hu, Qida ^a   Shen, Jie ^a   Jin, Xue ^a   Zhou, Jun ^a   Tang, Guping ^a,b   Chu, Paul K ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer treatment; Paclitaxel; SiRNA; Supramolecular micelles

Indexed keywords

GENE TRANSFER; MICELLES; ONCOLOGY; SUPRAMOLECULAR CHEMISTRY;

INTRACELLULAR TRAFFICKING; MICELLAR ASSEMBLIES; NON-VIRAL GENE DELIVERY; PACLITAXEL; PHYSICOCHEMICAL PROPERTY; SIRNA; SUPRAMOLECULAR MICELLES; SYNERGISTIC EFFECT;

DISEASES;

AMANTADINE; BETA CYCLODEXTRIN; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; PROTEIN BCL 2; SHORT HAIRPIN RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL MIGRATION; CHEMICAL PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; OVARY CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPRAMOLECULAR CHEMISTRY; SUPRAMOLECULAR MICELLAR ASSEMBLY;

EID: 84863579159     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.060     Document Type: Article

References (30)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
2. Huang C., Li M., Chen C., Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008, 12:637-645.
3. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011, 14:150-163.
4. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35:553-562.
5. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008, 12:463-476.
6. Xu Z., Zhang Z., Chen Y., Chen L., Lin L., Li Y. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials 2010, 31:916-922.
7. Xue H.Y., Wong H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011, 32:2662-2672.
8. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
9. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77:1561-1565.
10. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
11. Luo C., Wang Y., Chen Q., Han X., Liu X., Sun J., et al. Advances of paclitaxel formulations based on nanosystem delivery technology. Mini Rev Med Chem 2012, 12:434-444.
12. Heo D.N., Yang D.H., Moon H.J., Lee J.B., Bae M.S., Lee S.C., et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 2012, 33:856-866.
13. Zhang X.Q., Xu X., Lam R., Giljohann D., Ho D., Mirkin C.A. Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. ACS Nano 2011, 5:6962-6970.
14. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
15. Wang X., Li J., Wang Y., Koenig L., Gjyrezi A., Giannakakou P., et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5:6184-6194.
16. Chen Y., Bathula S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010, 285:22639-22650.
17. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
18. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Huang S.Y., et al. Simultaneous delivery of siRNA and paclitaxel via a " two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
19. Xiong X.B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
20. Huang H.Y., Kuo W.T., Chou M.J., Huang Y.Y. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A 2011, 97:330-338.
21. Hu Q.D., Fan H., Ping Y., Liang W.Q., Tang G.P., Li J. Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug. Chem Commun (Camb) 2011, 47:5572-5574.
22. Fan H., Hu Q.D., Xu F.J., Liang W.Q., Tang G.P., Yang W.T. In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL. Biomaterials 2012, 33:1428-1436.
23. Chen G., Jiang M. Cyclodextrin-based inclusion complexation bridging supramolecular chemistry and macromolecular self-assembly. Chem Soc Rev 2011, 40:2254-2266.
24. Tang G.P., Guo H.Y., Alexis F., Wang X., Zeng S., Lim T.M., et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J Gene Med 2006, 8:736-744.
25. Lin C., Engbersen J.F. Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J Control Release 2008, 132:267-272.
26. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
27. Kim E., Jung Y., Choi H., Yang J., Suh J.S., Huh Y.M., et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010, 31:4592-4599.
28. Ikeguchi M., Ueda T., Sakatani T., Hirooka Y., Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002, 11:33-40.
29. Rosa J., Canovas P., Islam A., Altieri D.C., Doxsey S.J. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006, 17:1483-1493.
30. Chen X.Q., Yang S., Li Z.Y., Lu H.S., Kang M.Q., Lin T.Y. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Rep 2012, 5:917-922.